Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 5/2012

01-10-2012 | Transplantation (A Pileggi, Section Editor)

Diabetes and Kidney Transplantation: Past, Present, and Future

Authors: Giselle Guerra, Amna Ilahe, Gaetano Ciancio

Published in: Current Diabetes Reports | Issue 5/2012

Login to get access

Abstract

Diabetes mellitus is the most common etiology for end stage renal disease (ESRD) worldwide and in the United States. The incidence of morbidity and mortality is higher in diabetic patients with ESRD due to increased cardiovascular events. Patients with type 2 diabetes who receive a renal allograft have a higher survival rate compared with patients who are maintained on chronic hemodialysis therapy, but there is scarcity of data on long-term graft outcomes. Most recently the development of new onset diabetes after transplantation (NODAT) poses a serious threat to patient and allograft survival. Pre-emptive transplantation and the use of living donors have improved overall survival. In addition, critical management of glucose, blood pressure, and cholesterol are some of the factors that can help minimize adverse outcomes in both patients with pre-existing diabetes and patients who develop NODAT. Future clinical trials are warranted to improve therapeutic medical management of these patients thus influencing graft attrition.
Literature
1.
National Institute of Health (NIH), (NIDDK): 2010 Annual Data Report: Atlas of end stage renal disease in the United States. In, National Institute of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). 2010.
2.
Coressh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease. JAMA. 2007;298:2038–47.CrossRef
3.
Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end stage renal disease: 25 year follow-up. Arch Intern Med. 2009;169:342.PubMedCrossRef
4.
Bash LD, Astor BC, Coresh J. Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2010;55:31–41.PubMedCrossRef
5.
Welsh RC, Cockfield SM, Campbell P, et al. Cardiovascular assessment of diabetic end stage renal disease patients before renal transplantation. Transplantation. 2011;9:213–8.CrossRef
6.
Wolfe RA, Ashby VB, Milford EL, Ojo AO, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. NEJM. 1999;341:1725–30.PubMedCrossRef
7.
Meier-Kriesche HU, Ojo AO, Port FK, et al. Survival improvement among patients with end stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol. 2001;12:1293–6.PubMed
8.
United Network for Organ Sharing. 2012 wait-list for kidney transplantation from organ procurement and transplantation network (OPTN) data, May, 2012.
9.
Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation. 2002;74:1377–81.PubMedCrossRef
10.
Son YK, Oh JS, Kim SM, et al. Clinical outcome of preemptive kidney transplantation in patients with diabetes mellitus. Transplant Proc. 2010;42:3497–502.PubMedCrossRef
11.
Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–85.PubMedCrossRef
12.
Ballard DJ, Humphrey LL, Melton III LJ, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population based in Rochester, Minnesota. Diabetes. 1988;37:405–12.PubMedCrossRef
13.
Poulsen PL, Hansen KW, Mogensen CE. Ambulatory blood pressure in the transition from normo to microalbuminuria. A longitudinal study in IDDM patients. Diabetes. 1994;43:1248–53.PubMedCrossRef
14.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–86.
15.
Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–62.PubMedCrossRef
16.
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med. 2001;345:861–9.CrossRef
17.
Wheeler DC, Steiger J. Evolution and etiology of cardiovascular diseases in renal transplant recipients. Transplantation. 2000;70:SS41.PubMed
18.
Foley RN, Murray AM, Li S, Herzog CA, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489–95.PubMedCrossRef
19.
Balasubramaniam K, Viswanathan G, Marshall S, et al. Increased atherotherombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract. 2012;2012:1–18.CrossRef
20.
21.
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–81.PubMedCrossRef
22.
Stegenga ME, van der Crabben SN, Dessing MD, et al. Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production, and neutrophil function in humans. Diabetic Med. 2008;25:157–64.PubMedCrossRef
23.
Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostatsis, and thrombosis. Thromb Haemaost. 2008;99:995–1000.
24.
Mutner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13:745–53.
25.
Kasiske BL, Maclean JR, Snyder JJ. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol. 2006;17:900–7.PubMedCrossRef
26.
Schnuell P, Lorenze D, Trede M, et al. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol. 1998;9:2135–41.
27.
McDonald SP, Russ GR. Survival of recipients of cadaveric kidney transplants compared with those receiving dialysis treatment in Australia and New Zealand, 1991–2001. Nephrol Dial Transplant. 2002;17:2212–9.PubMedCrossRef
28.
Hirschl M. Renal transplantation in patients with type 2 diabetes mellitus. Nephrol Dial Transplant. 1995;10 Suppl 7:58–60.PubMed
29.
• Weisbauer F, Heinze G, Regele H, et al. Glucose control is associated with patient survival in diabetic patients after renal transplantation. Transplantation. 2010;89:612–9. This paper described the effect of the best treatment strategy to improve outcome for diabetic transplant patients. CrossRef
30.
Cosio FG, Hisckson LJ, Griffin MD, et al. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant. 2008;8:593–9.PubMedCrossRef
31.
Aalten J, Hoogeveen EK, Roodnat JI, et al. Associations between pre-kidney transplant risk factors and posttransplant cardiovascular events and death. Transpl Int. 2008;21:985–91.PubMedCrossRef
32.
Kiverd B, Panek R. Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited. Clin J Am Soc Nephrol. 2008;3:822–8.CrossRef
33.
Shaffer D, Simpson MA, Madras PN, et al. Kidney transplantation in diabetic patients using cyclosporine. Five-year follow-up. Arch Surg. 1995;130:28–287.CrossRef
34.
Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Kidney transplantation halts cardiovascular disease progression in patients with end stage renal disease. Am J Transplant. 2004;4:1662–8.PubMedCrossRef
35.
Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation. 2003;75:1291–5.PubMedCrossRef
36.
Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;2:807–18.PubMedCrossRef
37.
Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regime: incidence, risk factors, progression, and prognosis. Transplantation. 2003;76:375–82.PubMedCrossRef
38.
Fl L, Samaniego M. Transplantation in diabetic kidney failure patients: modalities, outcomes, and clinical management. Semin Dial. 2010;23:198–205.CrossRef
39.
Barbosa J, Steffers MW, Sutherland DE, et al. Effect of glycemic control on early diabetic renal lesions. A 5-year randomized controlled clinical trial of insulin-dependent diabetic kidney transplant recipients. JAMA. 1994;272:600.PubMedCrossRef
40.
Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64:979–83.PubMedCrossRef
41.
Duijnhoven EM, Boots JM, Christiaans MH, et al. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol. 2001;12:583–8.PubMed
42.
Dumler F, Kilates C. Metabolic and nutritional complications of renal transplantation. J Ren Nutr. 2007;17:97–102.PubMedCrossRef
43.
•• Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012;335:1638–43. This paper illustrates how mTORC2 disruption could be relevant for the pathogenesis of type II diabetes and metabolic syndrome. PubMedCrossRef
44.
Hughes K, Kennedy B. Rapamycin paradox resolved. Cell Biol. 2012;335:1578–9.
45.
Kuo HT, Sampaio MS, Vincent F, et al. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OTN/UNOS) Database. Am J Kidney Dis. 2010;56:1127–39.PubMedCrossRef
46.
Parekh J, Bostrom A, Feng S. Diabetes mellitus: a risk factor for delayed graft function after deceased donor kidney transplantation. Am J Transpl. 2010;10:298–303.CrossRef
47.
Thomas MC, Mathew TH, Russ GR, et al. Early perioperative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation. 2001;72:1321–4.PubMedCrossRef
48.
Troppman C, Gillingham KJ, Benedetti E, et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis. Transplantation. 1995;59:962.CrossRef
49.
Kyriakides G, Simmons R, Najarian J. Wound infections in renal transplant wounds: pathogenetic and prognostic factors. Ann Surg. 1975;182:770–5.PubMedCrossRef
50.
Roine E, Bjork IT, Oyen O. Targeting risk factors for impaired wound healing and wound complications after kidney transplantation. Transplant Proc. 2010;42:2542–6.PubMedCrossRef
51.
Lansang C, Ma L, Schold J, et al. The relationship between diabetes and infectious hospitalizations in renal transplant recipients. Diabetes Care. 2006;29:1659–60.PubMedCrossRef
52.
Abbot KC, Hypolite I, Tveit DJ, et al. Hospitalizations for fungal infections after initiation of chronic dialysis in the United States. Nephron. 2001;89:426–32.CrossRef
53.
Ersoy A, Ersoy C, Tekce H, et al. Diabetic ketoacidosis following development of de novo diabetes in renal transplant recipient associated with tacrolimus. Transplant Proc. 2004;36:1407–10.PubMedCrossRef
54.
Mazali FC, Lalli CA, Alves-Filho G, et al. Posttransplant diabetes mellitus: incidence and risk factors. Transplant Proc. 2008;40:764–6.PubMedCrossRef
55.
Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A, et al. Daclizumab induction, tacrolimus, mycophenolate mofetil, and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation. 2002;73:1100–6.PubMedCrossRef
56.
Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roth D, Kupin W, et al. A randomized long-term trial of tacrolimus/sirolimus vs tacrolimus/mycophenolate mofetil vs cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation. 2004;77:252–8.PubMedCrossRef
57.
Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, et al. A randomized trial of 3 renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation. 2005;80:457–65.PubMedCrossRef
58.
Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, et al. Randomized trial of mycophenolate mofetil vs enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: 1 year follow-up. Transplantation. 2008;86:67–74.PubMedCrossRef
59.
• Ciancio G, Gaynor JJ, Sageshima J, Guerra G, Zarak A, Roth D, et al. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. Transplantation. 2011;92:1348–57. This study assessed the degree of NODAT incidence after early steroid withdrawal using double induction. PubMedCrossRef
60.
Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among US wait-listed and transplant renal allograft recipients. Am J Transplant. 2003;3:590–8.PubMedCrossRef
61.
Luan FL, Zhang H, Schaubel DE, et al. Comparative risk of impaired glucose metabolism associated with cyclosporine vs tacrolimus in the late posttransplant period. Am J Transplant. 2008;8:1871–7.PubMedCrossRef
62.
Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: a systemic review of the literature. Diabetes Care. 2002;25:583–92.PubMedCrossRef
63.
Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine vs tacrolimus. Am J Transplant. 2007;7:1506–14.PubMedCrossRef
64.
Perez-Flores I, Sanchez Fructuoso A, Calvo EF, et al. Incidence and risk factors for the metabolic syndrome and posttransplant diabetes in renal transplant recipients taking tacrolimus. Transplant Proc. 2010;42:2902–4.PubMedCrossRef
65.
Hur KY, Kim MS, Kim YS, et al. Risk factors associated with the onset and progression of posttranplant diabetes in renal allograft recipients. Diabetes Care. 2007;30:609.PubMedCrossRef
66.
Shah T, Kasravi A, Huang E, et al. Risk factors development of new onset diabetes mellitus after kidney transplantation. Transplantation. 2006;82:1673.PubMedCrossRef
67.
Joss N, Staatz CE, Thomson AH, et al. Predictors of new onset diabetes after renal transplantation. Clin Transplant. 2007;21:136.PubMedCrossRef
68.
Hjelmesaeth J, Harmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64:979–83.PubMedCrossRef
69.
Duijnhoven EM, Boots JM, Christiaans MH, et al. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol. 2001;12:583–8.PubMed
70.
Menegazzo LA, Ursich MJ, Fukui RT, et al. Mechanism of the diabetogenic action of cyclosporine A. Horm Metab Res. 1998;30:663–7.PubMedCrossRef
71.
Teutonico A, Schena FP, Paraskevas S, et al. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol. 2005;16:3128–35.PubMedCrossRef
72.
Van Duijnhoven EM, Christiaans MHL, Boots JMM, et al. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus vs cyclosporine based immunosuppression. J Am Soc Nephrol. 2002;13:213–20.PubMed
73.
Gelens M, Christiaans MHL, van Hooff, et al. Does switching the primary immunosupressant from tacrolimus to cyclosporine in renal recipients who develop PTDM confer any therapeutic advantage? 6th International Conference on New Trends in Immunosuppression. Austria: Salzburg; 2004. Book of Abstracts, p59.
74.
Pirsch JD, Miller J, Deieerhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 1997;63:977–83.PubMedCrossRef
75.
Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil vs cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation. 2000;69:834–41.PubMedCrossRef
76.
Gonwa T, Mendez R, Yang HC, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation. 2003;75:1213–20.PubMedCrossRef
77.
Miller J, Mendez R, Pirsch JD, et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. Transplantation. 2000;69:875–80.PubMedCrossRef
78.
Rostaing L, Cantarovich D, Mourad G, et al. Steroid free immunosuppression with a combination of daclizumab, tacrolimus, and MMF is efficacious and safe: results of a large multicenter trial in renal transplantation. Am J Transplant. 2003;3 Suppl 5:312.
79.
Chang RW, Snowden S, Palmer A, et al. European randomized trial of dual vs triple tacrolimus based regimens for control of acute rejection in renal allograft recipients. Transpl Int. 2001;14:384–90.PubMedCrossRef
80.
Wlodarczyk Z, Walaszewski J, Perner F, et al. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus treated kidney transplant recipients. Ann Transplant. 2002;7:28–31.PubMed
81.
Klinger M, Vitko S, Salmela K, et al. Large prospective study evaluating steroid-free immunosuppression with tacrolimus/basiliximab and tacrolimus/MMF compared with tacrolimus/MMF/steroids in renal transplantation. Nephrol Dial Transplant. 2003;18 Suppl 4:788.
82.
Backman L. Post-transplant diabetes mellitus: the last 10 years with tacrolimus. Nephrol Dial Transplant. 2004;19:vi13–6.PubMedCrossRef
83.
Van Hoof JP, Christiaans MH, van Duijnhoven EM. Evaluating mechanisms posttransplant diabetes mellitus. Neprhol Dial Transplant. 2004;19 Suppl 6:vi8–vi12.CrossRef
84.
Araki M, Slechner S, Ismail H, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation. 2005;81:335–41.CrossRef
85.
Tsao JP, Lian JD, Wu SW, et al. Long-term impact of pretransplant and posttransplant diabetes mellitus on kidney transplant outcomes. World J Surg. 2011;35:2818–25.CrossRef
86.
Davidson J, Wilkinson A, Dantal J, et al. New onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain. 19 February 2003. Transplantation. 2003;75:SS3–24.
87.
Becker BN, Rush SH, Dykstra DM, et al. Preemptive transplantation for patients with diabetes-related kidney disease. Arch Intern Med. 2006;166:44–8.PubMedCrossRef
88.
Wiseman AC, Gralla J. Simultaneous pancreas kidney transplant vs other kidney transplant options in patients with type 2 diabetes. CJASN. 2012;7:656–64.PubMed
89.
Wissing KM, Abramowicz D, Broeders N, et al. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation. 2000;70:464–72.PubMedCrossRef
90.
Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int. 1998;53:217–22.PubMedCrossRef
91.
Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: report from the managing dyslipidemias in chronic kidney disease work group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4 Suppl 7:13–53.PubMedCrossRef
92.
K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1–290.
93.
Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004;43:1071–81.PubMedCrossRef
94.
Rao PS, Schaubel DE, Jia X, et al. Survival on dialysis post-kidney transplant failure: results from the Scientific Registry of Transplant Recipients. Am J Kidney Dis. 2007;49:294–300.PubMedCrossRef
95.
Ojo AO, Wolfe RA, Agodoa LY, et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the Unite States Renal Data System. Transplantation. 1998;66:1651–9.PubMedCrossRef
96.
Su VCH, Harrison J, Rogers C, et al. Belatacept: a new biologic and its role in kidney transplantation. Ann Pharmacother. 2012;46:57–67.PubMedCrossRef
Metadata
Title
Diabetes and Kidney Transplantation: Past, Present, and Future
Authors
Giselle Guerra
Amna Ilahe
Gaetano Ciancio
Publication date
01-10-2012
Publisher
Current Science Inc.
Published in
Current Diabetes Reports / Issue 5/2012
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-012-0306-3

Other articles of this Issue 5/2012

Current Diabetes Reports 5/2012 Go to the issue

Transplantation (A Pileggi, Section Editor)

Autologous Regulatory T Cells for the Treatment of Type 1 Diabetes

Treatment of Type 1 Diabetes (D Dabelea, Section Editor)

Adipose Tissue, Hormones, and Treatment of Type 1 Diabetes

Treatment of Type 1 Diabetes (D Dabelea, Section Editor)

Current Concepts and Controversies in Prevention and Treatment of Diabetic Ketoacidosis in Children

Treatment of Type 1 Diabetes (D Dabelea, Section Editor)

Stem Cell Educator Therapy and Induction of Immune Balance

Transplantation (A Pileggi, Section Editor)

Transplantation of the Pancreas

Erratum

Erratum to: Understanding Pancreas Development for β-Cell Repair and Replacement Therapies
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits